Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Clarity Pharmaceuticals Ltd. ( (AU:CU6) ) has issued an update.
Clarity Pharmaceuticals Ltd. announced that Cabbit Pty Ltd ITF Robwill Trust has ceased to be a substantial holder in the company as of August 1, 2025. This change was due to a dilution of shares following a placement announced on July 28, 2025, which affected 17,911,280 fully paid ordinary shares. This development may impact the company’s shareholder structure and influence its market positioning.
The most recent analyst rating on (AU:CU6) stock is a Buy with a A$8.20 price target. To see the full list of analyst forecasts on Clarity Pharmaceuticals Ltd. stock, see the AU:CU6 Stock Forecast page.
More about Clarity Pharmaceuticals Ltd.
Clarity Pharmaceuticals Ltd. operates in the pharmaceutical industry, focusing on the development and commercialization of radiopharmaceuticals for the treatment of serious diseases. The company is dedicated to advancing its proprietary platform to improve patient outcomes in oncology and other therapeutic areas.
Average Trading Volume: 3,098,329
Technical Sentiment Signal: Buy
Current Market Cap: A$1.4B
See more data about CU6 stock on TipRanks’ Stock Analysis page.